Hong Kong Auto Stock News

SEHK:8418
SEHK:8418Specialty Retail

Discover Asian Penny Stocks With Market Caps Under US$700M

As global markets navigate a landscape marked by inflation concerns and geopolitical tensions, the Asian market remains a focal point for investors seeking growth opportunities. Penny stocks, often representing smaller or newer companies, continue to intrigue those looking for potential value beyond mainstream investments. Despite their vintage name, these stocks can offer surprising resilience and stability when backed by strong financials. This article explores three such penny stocks in...
SEHK:6808
SEHK:6808Consumer Retailing

Sun Art Retail Group (SEHK:6808) Valuation After Weak Full Year Results And Store Transformation Plans

Sun Art Retail Group (SEHK:6808) has drawn attention after reporting full year results to March 31, 2026. Sales were lower year on year and the company moved from a profit to a net loss. See our latest analysis for Sun Art Retail Group. At a share price of HK$1.48, Sun Art Retail Group has seen a 1-month share price return of 4.23%. However, the share price is down 14.94% year to date and the 1-year total shareholder return has fallen 25.47%, pointing to fading momentum despite management’s...
SEHK:1810
SEHK:1810Tech

Xiaomi (SEHK:1810) One Off Gain Driven Margin Jump Tests Bullish Profitability Narrative

Xiaomi (SEHK:1810) has just wrapped up FY 2025 with fourth quarter revenue of CN¥116.9b and basic EPS of CN¥0.25, capping a year in which trailing twelve month revenue reached CN¥457.3b and EPS stood at CN¥1.62 alongside year on year earnings growth of 76%. Over recent periods the company has seen quarterly revenue move from CN¥92.5b in Q3 2024 to CN¥109.0b in Q4 2024 and then into the CN¥111.3b to CN¥116.9b range through FY 2025. Over the same time, trailing net profit margin has shifted...
SEHK:3692
SEHK:3692Pharmaceuticals

Hansoh Pharmaceutical Group’s Valuation After HS-10541 Clinical Trial Approval For KRAS G12C Tumors

Hansoh Pharmaceutical Group (SEHK:3692) has drawn fresh investor attention after announcing that its self developed Class 1 drug candidate HS-10541 received clinical trial approval in China for KRAS G12C mutated advanced solid tumors. See our latest analysis for Hansoh Pharmaceutical Group. The HS-10541 trial approval comes as Hansoh Pharmaceutical Group's share price has softened recently, with a 30 day share price return down 13.62%, even while the 1 year total shareholder return stands at...
SEHK:9660
SEHK:9660Software

Asian Growth Companies With High Insider Ownership In May 2026

As the Asian markets navigate a complex landscape of geopolitical tensions and economic uncertainties, investors are increasingly focused on companies with strong growth potential and significant insider ownership. In this environment, stocks that combine robust internal backing with promising expansion prospects can offer a compelling investment narrative.
SEHK:862
SEHK:862IT

Xtep International Holdings And 2 Other Asian Penny Stocks Worth Watching

As global markets navigate a complex landscape marked by inflation concerns and geopolitical tensions, the Asian market remains a focal point for investors seeking opportunities in emerging sectors. Penny stocks, though an older term, continue to represent smaller or less-established companies that can offer significant value and growth potential. By focusing on those with robust financials and clear growth trajectories, investors might uncover promising opportunities among these lesser-known...
SEHK:2600
SEHK:2600Metals and Mining

A Look At Aluminum Corporation of China (SEHK:2600) Valuation After EV Demand Fuels Talk Of A Technical Rebound

Electric vehicle demand and technical rebound thesis Recent analyst commentary on Aluminum Corporation of China (SEHK:2600) discusses a potential technical rebound, connecting current interest in the stock to aluminum demand associated with the expanding electric vehicle industry. See our latest analysis for Aluminum Corporation of China. At the latest share price of HK$11.88, the stock has seen a sharp 1-day share price return of 9.29% and 7-day share price return of 14.56%, even though the...
SEHK:2696
SEHK:2696Biotechs

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Positive EMA CHMP Opinion For Serplulimab

Shanghai Henlius Biotech (SEHK:2696) is back on investors’ radar after winning a positive opinion from the EMA’s CHMP for serplulimab plus chemotherapy in first-line advanced squamous non-small cell lung cancer in Europe. See our latest analysis for Shanghai Henlius Biotech. Despite the positive CHMP opinion and a series of product updates, Shanghai Henlius Biotech’s short term share price return has come under pressure, with the 1 month share price return down 17.22%. However, the 1 year...
SEHK:9885
SEHK:9885Healthcare

Nickel Asia And 2 Other Penny Stocks Making Waves In Global

Amidst a backdrop of rising inflation worries and fluctuating consumer sentiment, global markets have shown resilience, with major U.S. stock indexes reaching new highs and small-cap stocks outperforming their larger peers. In such a dynamic market landscape, investors often look beyond the well-trodden paths to discover potential in lesser-known areas like penny stocks. While the term "penny stocks" might seem outdated, these smaller or newer companies can offer unique growth opportunities...
SEHK:700
SEHK:700Interactive Media and Services

A Look At Tencent Holdings (SEHK:700) Valuation After Q1 Results And Renewed Dungeon&Fighter Deal

Earnings and gaming deal put Tencent in focus Tencent Holdings (SEHK:700) has drawn fresh attention after reporting first quarter 2026 results, alongside a ten year renewal of its Dungeon&Fighter publishing partnership with NEXON in China, a combination that keeps its gaming business in clear view for investors. See our latest analysis for Tencent Holdings. Despite the Q1 earnings update and the renewed Dungeon&Fighter deal, Tencent’s share price has been under pressure, with the stock down...